R3HCC1L Antibody

What is R3HCC1L and why is it studied?

R3HCC1L (R3H and coiled-coil domain-containing protein 1-like), also known by several synonyms including C10orf28 (chromosome 10 open reading frame 28) and GIDRP88 (growth inhibition and differentiation-related protein 88), is a 792 amino acid protein that exists in three alternatively spliced isoforms . The gene encoding R3HCC1L maps to human chromosome 10, which spans nearly 135 million base pairs and constitutes approximately 4.5% of total cellular DNA . This chromosome encodes nearly 1,200 genes including those for chemokines, cadherins, excision repair proteins, early growth response factors, and fibroblast growth receptors . R3HCC1L is studied partly because it is located on chromosome 10, which is associated with several genetic disorders including Charcot-Marie Tooth disease, Jackson-Weiss syndrome, Usher syndrome, and multiple endocrine neoplasia type 2 .

What are the common types of R3HCC1L antibodies available for research?

R3HCC1L antibodies are commercially available in several formats, with the most common being rabbit polyclonal antibodies . While the search results don't explicitly mention all available types for R3HCC1L specifically, research indicates that antibodies generally fall into three categories: polyclonal, monoclonal, and recombinant . Current research suggests that recombinant antibodies typically perform better than monoclonal or polyclonal antibodies in validation studies, although this may vary by target protein . For R3HCC1L research, polyclonal antibodies from rabbit hosts are documented in commercial offerings .

What applications are R3HCC1L antibodies validated for?

According to product documentation, commercially available R3HCC1L antibodies are validated for applications including Enzyme-Linked Immunosorbent Assay (ELISA) and Immunohistochemistry (IHC) . While not specifically validated for R3HCC1L antibodies in the provided search results, common antibody applications in research generally include Western blot (WB), immunoprecipitation (IP), and immunofluorescence (IF) . When selecting an R3HCC1L antibody, researchers should carefully review the validation data for their specific application of interest to ensure optimal performance.

How can I validate the specificity of an R3HCC1L antibody for my research?

Validating antibody specificity is crucial for reliable research outcomes. The optimal methodology for antibody validation, applicable to R3HCC1L antibodies, involves comparing results between wild-type cells and an isogenic CRISPR knockout (KO) version of the same cells . This approach provides rigorous and broadly applicable results that can confirm antibody specificity.

The validation process should include:

• Generation of R3HCC1L knockout cell lines using CRISPR-Cas9 technology

• Testing the antibody on both wild-type and knockout samples using your application of interest (e.g., Western blot, immunofluorescence)

• Confirming the absence of signal in knockout samples while maintaining signal in wild-type samples

• Evaluating cross-reactivity by checking for non-specific bands or signals

While this method is considered gold standard, it is more costly than alternative approaches due to the need for custom engineered cell lines . For Western blot validation specifically, antibodies should be tested on cell lysates for intracellular proteins or cell media for secreted proteins to verify detection of the cognate protein .

What are the potential cross-reactivity issues with R3HCC1L antibodies?

Cross-reactivity is a significant concern with antibodies, including those targeting R3HCC1L. Large-scale antibody validation studies have revealed that more than 50% of commercial antibodies fail in one or more applications due to specificity issues . For R3HCC1L specifically, there are two potential cross-reactivity scenarios:

• Specific, selective antibodies: These successfully detect R3HCC1L without recognizing unrelated proteins

• Specific, non-selective antibodies: These detect R3HCC1L but also recognize unrelated proteins, showing non-specific bands that remain present in knockout controls

To address cross-reactivity concerns, researchers should:

• Perform validation using knockout controls

• Test multiple antibodies against R3HCC1L from different manufacturers

• Use positive controls with known R3HCC1L expression

• Consider the specific application requirements, as an antibody might perform well in one application (e.g., IHC) but show cross-reactivity in another (e.g., Western blot)

How does the performance of R3HCC1L antibodies compare across different experimental techniques?

While performance data specific to R3HCC1L antibodies across different techniques is not provided in the search results, general trends in antibody performance suggest application-specific variability . The performance of antibodies, including those targeting R3HCC1L, can vary significantly between applications like Western blot, immunoprecipitation, and immunofluorescence.

Research indicates that approximately two-thirds of proteins can be covered by at least one high-performing antibody, and half can be covered by at least one high-performing renewable antibody . For optimal results, researchers should:

• Test multiple antibodies for each application

• Validate each antibody specifically for the intended application

• Consider that an antibody performing well in ELISA may not perform equally well in IHC

• Optimize protocols for each application (buffer compositions, incubation times, etc.)

For R3HCC1L specifically, commercially available antibodies have been validated for ELISA and IHC applications , but performance in other applications would require additional validation by the researcher.

What is the optimal storage and handling protocol for R3HCC1L antibodies?

Proper storage and handling of R3HCC1L antibodies are essential for maintaining their performance over time. According to product documentation, R3HCC1L antibodies should be stored at -20°C or -80°C upon receipt . Repeated freeze-thaw cycles should be avoided as they can degrade antibody quality and performance .

R3HCC1L antibodies are typically supplied in liquid form with a diluent buffer consisting of pH 7.4 PBS, 0.05% NaN3, and 40% Glycerol . This buffer composition helps maintain antibody stability during storage. When handling these antibodies, researchers should:

• Aliquot the antibody into smaller volumes upon receipt to minimize freeze-thaw cycles

• Thaw aliquots gradually at cold temperatures (4°C) rather than at room temperature

• Maintain sterile handling conditions to prevent contamination

• Follow manufacturer's recommendations for long-term storage

• Check expiration dates and validation status periodically

What experimental controls should be included when using R3HCC1L antibodies?

Rigorous experimental controls are crucial for ensuring reliable results when using R3HCC1L antibodies. Based on best practices in antibody-based research, the following controls should be included:

• Positive control: Samples known to express R3HCC1L, such as specific human or mouse tissues/cell lines with confirmed expression

• Negative control: Samples known not to express R3HCC1L or ideally CRISPR knockout cell lines lacking R3HCC1L expression

• Isotype control: An antibody of the same isotype (IgG for R3HCC1L antibodies ) but with irrelevant specificity

• Secondary antibody only control: To assess background staining from the secondary detection system

• Peptide competition/blocking: Using the immunogen peptide to confirm specificity by competing for antibody binding

For R3HCC1L antibodies specifically, which are reported to react with human and mouse samples , using appropriate species-matched controls is essential. The inclusion of CRISPR knockout controls for R3HCC1L would provide the most rigorous validation of antibody specificity .

How can computational models improve R3HCC1L antibody design and selection?

While not specific to R3HCC1L antibodies, emerging computational approaches are revolutionizing antibody design and selection. Recent advancements in antibody modeling, such as the DyAb system, demonstrate how sequence-based models can predict antibody properties and guide the design of variants with improved binding affinity .

For researchers working with R3HCC1L antibodies, these computational approaches could potentially:

• Guide the selection of optimal antibody candidates from existing commercial options

• Predict cross-reactivity based on sequence homology with other proteins

• Inform antibody engineering efforts to improve specificity for R3HCC1L

• Design custom R3HCC1L antibodies with enhanced properties for specific applications

The DyAb model, for example, has shown success in predicting antibody affinity improvements with Pearson correlation coefficients up to 0.84 between predicted and measured improvements . Similar approaches could potentially be applied to R3HCC1L antibodies to identify optimal variants or design improved versions with higher specificity or affinity.

What are common causes of false positive or negative results with R3HCC1L antibodies?

False results when using R3HCC1L antibodies can arise from multiple sources. Based on general antibody research and validation studies, common causes include:

False Positives:

• Cross-reactivity with structurally similar proteins

• Non-specific binding due to high antibody concentration

• Inadequate blocking leading to background signal

• Secondary antibody cross-reactivity

• Sample overloading in Western blots

False Negatives:

• Low expression of R3HCC1L in the sample

• Epitope masking due to protein folding or post-translational modifications

• Antibody degradation due to improper storage

• Incompatible fixation methods destroying the epitope

• Suboptimal detection systems

Large-scale antibody validation studies have found that more than 50% of commercial antibodies fail in one or more applications , highlighting the importance of proper validation before experimental use. For R3HCC1L research, using knockout controls is particularly valuable for distinguishing between true and false signals .

How can I optimize immunohistochemistry protocols for R3HCC1L detection?

Optimizing immunohistochemistry (IHC) protocols for R3HCC1L detection requires careful consideration of several parameters. While specific optimization data for R3HCC1L antibodies is not provided in the search results, the following methodological approach is recommended based on general antibody optimization principles:

• Antigen retrieval optimization:

  • Test both heat-induced epitope retrieval (HIER) and enzymatic retrieval methods

  • Compare citrate buffer (pH 6.0) versus EDTA buffer (pH 9.0) for optimal epitope exposure

  • Optimize retrieval time and temperature

• Antibody dilution optimization:

  • Perform titration experiments with dilutions ranging from 1:100 to 1:2000

  • The commercially available R3HCC1L antibody is reportedly reactive with human and mouse samples

  • Include positive and negative controls at each dilution

• Incubation conditions:

  • Compare overnight incubation at 4°C versus shorter incubations at room temperature

  • Test various blocking reagents to minimize background

• Detection system selection:

  • Compare sensitivity of different detection systems (polymer-based versus ABC method)

  • Optimize visualization reagent concentration and development time

• Counterstaining optimization:

  • Adjust hematoxylin concentration and staining time for optimal nuclear visualization without obscuring R3HCC1L staining

Document all optimization steps systematically and select the conditions providing the best signal-to-noise ratio with confirmed specificity through knockout controls when possible .

What are emerging technologies for improving R3HCC1L antibody specificity and performance?

Emerging technologies relevant to improving R3HCC1L antibody specificity and performance include several innovative approaches:

• Recombinant antibody development: Research indicates that recombinant antibodies generally perform better than monoclonal or polyclonal antibodies . Engineering recombinant versions of R3HCC1L antibodies could improve specificity and reproducibility.

• AI-driven antibody design: Models like DyAb demonstrate the potential of computational approaches to design antibodies with improved properties . These models could be applied to develop enhanced R3HCC1L antibodies by:

  • Predicting mutations that improve binding affinity

  • Identifying structural elements that enhance specificity

  • Generating novel antibody variants with optimized properties

• CRISPR-based validation platforms: Expanding the use of CRISPR knockout cell lines for antibody validation provides the most rigorous approach to confirming specificity .

• Multimodal validation: Combining multiple validation approaches (knockout controls, orthogonal methods, etc.) to comprehensively assess antibody performance.

• Standardized reporting: Implementing comprehensive antibody validation reporting standards to improve transparency and reproducibility in research.

These technologies could significantly advance the reliability of R3HCC1L antibody-based research and address the broader reproducibility crisis in antibody-based studies, where approximately $1.75 billion is wasted yearly on non-specific antibodies .

What is known about the role of R3HCC1L in disease processes and its potential as a biomarker?

While the search results don't provide specific information about R3HCC1L's role in disease processes or its potential as a biomarker, general information about its genomic location offers some context. R3HCC1L (also known as C10orf28 or GIDRP88) is encoded on chromosome 10, which is associated with several genetic disorders .

The name "growth inhibition and differentiation-related protein 88" (GIDRP88) suggests potential roles in cellular growth regulation and differentiation processes, which could be relevant to disease mechanisms . Additionally, its alternative name "putative mitochondrial space protein 32.1" indicates possible mitochondrial localization, potentially connecting it to mitochondrial disorders .

Given that chromosome 10 genetic defects are associated with multiple conditions including Charcot-Marie Tooth disease, Usher syndrome, Cowden syndrome, multiple endocrine neoplasia type 2, and porphyria , further research into R3HCC1L's specific role in these or related disorders would be valuable. Reliable antibodies against R3HCC1L will be essential tools for investigating:

• Expression patterns across tissues in normal and disease states

• Subcellular localization and protein interactions

• Post-translational modifications in various physiological conditions

• Potential diagnostic or prognostic value in specific diseases

Current understanding of R3HCC1L function appears limited, presenting opportunities for future research using validated antibody tools.

What key factors should researchers consider when selecting and using R3HCC1L antibodies?

When selecting and using R3HCC1L antibodies, researchers should carefully consider several key factors to ensure experimental reliability and reproducibility:

• Antibody validation status: Prioritize antibodies with rigorous validation, particularly those tested against knockout controls . For R3HCC1L antibodies, confirm that validation data is available for your specific application of interest.

• Antibody format: Consider that recombinant antibodies generally outperform monoclonal and polyclonal formats , although R3HCC1L antibodies are commonly available as rabbit polyclonal antibodies .

• Application specificity: Select antibodies validated specifically for your intended application, recognizing that performance can vary significantly between applications such as ELISA, IHC, Western blot, IP, and IF .

• Appropriate controls: Implement rigorous experimental controls including positive, negative, and technical controls to ensure result validity.

• Optimization requirements: Plan for application-specific optimization of protocols including antibody concentration, incubation conditions, and detection methods.

• Species reactivity: Confirm the antibody's reactivity with your species of interest, noting that commercial R3HCC1L antibodies are reported to react with human and mouse samples .

• Storage and handling: Follow manufacturer recommendations for proper storage and handling to maintain antibody performance over time.